GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS - Test2 - elhamkhani - TriplyDB

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

http://www.wikidata.org/entity/Q21129334

about

Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging Diverse molecular targets for therapeutic strategies in Alzheimer's disease Small GSK-3 Inhibitor Shows Efficacy in a Motor Neuron Disease Murine Model Modulating Autophagy Cell migration in paediatric glioma; characterisation and potential therapeutic targeting.Glaucoma: the retina and beyond Knockdown of GSK3β increases basal autophagy and AMPK signalling in nutrient-laden human aortic endothelial cells Point mutations in the tumor suppressor Smad4/DPC4 enhance its phosphorylation by GSK3 and reversibly inactivate TGF-β signaling Peripheral nervous system plasmalogens regulate Schwann cell differentiation and myelination.Bioactive marine drugs and marine biomaterials for brain diseases The fibroblast growth factor 14·voltage-gated sodium channel complex is a new target of glycogen synthase kinase 3 (GSK3).Arrhythmogenic right ventricular cardiomyopathy mutations alter shear response without changes in cell-cell adhesion.Synthesis and Initial in Vivo Studies with [(11)C]SB-216763: The First Radiolabeled Brain Penetrative Inhibitor of GSK-3.GSK-3β and memory formation Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by disrupting centrosome regulation in cancer cells.Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer's disease.Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression.HIV-1-Tat Protein Inhibits SC35-mediated Tau Exon 10 Inclusion through Up-regulation of DYRK1A Kinase.Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo.Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies Inactivation of nuclear GSK3β by Ser(389) phosphorylation promotes lymphocyte fitness during DNA double-strand break response Glycogen synthase kinase-3: a potential preventive target for prostate cancer management Lithium Promotes Longevity through GSK3/NRF2-Dependent Hormesis.Regulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-3.Central role for GSK3β in the pathogenesis of arrhythmogenic cardiomyopathy.Marine Fungi as Producers of Benzocoumarins, a New Class of Inhibitors of Glycogen-Synthase-Kinase 3β.Neurotrophic natural products: chemistry and biology.DISC1 as a therapeutic target for mental illnesses.Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice.Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.The emerging role of dopamine-glutamate interaction and of the postsynaptic density in bipolar disorder pathophysiology: Implications for treatment.Glycogen synthase kinase-3 as a therapeutic target for cognitive dysfunction in neuropsychiatric disorders.Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases Arrhythmogenic Cardiomyopathy - New Insights into Disease Mechanisms and Drug Discovery.Personalized Medicine and Resurrected Hopes for the Management of Alzheimer's Disease: A Modular Approach Based on GSK-3β Inhibitors.Facile and Divergent Synthesis of Lamellarins and Lactam-Containing Derivatives with Improved Drug Likeness and Biological Activities.Imidazoline scaffold in medicinal chemistry: a patent review (2012-2015).Targeting hepatic glucose metabolism in the treatment of type 2 diabetes.MicroRNA cluster miR-17-92 Cluster in Exosomes Enhance Neuroplasticity and Functional Recovery After Stroke in Rats.Stressed and Inflamed, Can GSK3 Be Blamed?

P2860

Q26749755-89FF13A6-AC96-4BDB-AB69-3759CB23DD5E Q26768475-9BE8DE90-3B0A-44D1-9984-0F6F819B044F Q26827193-C9D62BCD-5D2B-44AB-84DB-D79DC23DF5A1 Q27322519-44C36113-25F0-44FF-9F9F-DEAD09613C5C Q27332147-090E7286-0B95-498B-A527-D7BA89929938 Q28077518-25638230-21DF-41C9-B55B-C6D1A7C10243 Q28830062-E87CDA5E-A3A0-41C0-9E65-8835E35E18F6 Q28834186-EC6ADD08-9FC4-4E0F-B3EE-E9455EBDFEA8 Q33685924-4D80D150-C9B3-4A29-8A33-8C36E4685E50 Q33736687-7BBDE899-0DAB-4AC6-A03C-655AF8E78D28 Q34703974-13D78A9C-0E47-46BB-B1FC-DA225675BA6E Q34974510-FBA253E4-B126-4276-ACAB-F9781CAB7F5C Q35615152-FBE52168-6E4E-4C66-8C3E-0B9BBD6648BC Q35904141-C0B0F64C-342E-4871-A3C2-3F7825A7FDC8 Q35979303-1AFF463B-D09F-4381-B4C6-FA38AAC70C2F Q36295178-BB8410CD-CAF4-4C10-9A08-44815B3D088A Q36339761-B27CCD06-5650-4A1B-BD72-52FF2477B02A Q36407266-275A1BA7-AB92-4FD6-B52C-3C9955759DC3 Q36415259-ED7B2813-964A-46B6-8B49-CA2D8503B123 Q36526315-2B11A284-C252-4181-B181-E2D625922CBE Q36540443-E910442F-0DE5-4326-A462-47C0DA2B2F6F Q36580561-9E9894BC-735E-48C2-B839-957A4FE9789A Q36850239-CCA81ECB-2907-4E80-9F67-94A366CEC9B3 Q36863419-40A548FF-D91D-4B51-BBD1-9FDCB4D9C814 Q36884231-0FADEA2B-883B-4FE8-8441-79DB98004A89 Q37453610-E38D1AF1-5216-4CAC-9A9C-1A542687B0D7 Q37623342-09630430-CA43-42B5-A3A4-E855FB3AE573 Q37698116-0DC810A3-1D98-4B0E-A018-A4A4A7480C80 Q37711788-7B41DE2E-CCB5-4706-A547-FB13BCF3C64D Q38126701-1CA7EB7D-5C38-4113-8ED2-DC0B7D79B4D7 Q38189780-5542FC55-3E46-4572-BA58-C4C318B641DF Q38266162-1B29B4BC-316D-413F-AA68-DD7219AF071B Q38272835-DDF1914B-BE4E-41E6-96FF-AA1803C32F13 Q38288215-C289186A-3BCB-405C-8325-F6724563D16F Q38608683-E3B6CBA4-8A32-4ADB-A61F-BEED76683258 Q38852108-77527B42-5854-429A-AA8C-8575BA160533 Q38887608-221BEBC4-0BF6-4B59-8A86-6E403D6D145F Q38925481-3D56DE54-149C-48D7-8B76-9D0F782F2F2D Q38945192-F32FA3A1-07D3-4617-8149-9E9472D306DA Q39017112-0B357F0D-AAD7-4F3E-AA71-9676D3EBFADD

P2860

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

http://www.wikidata.org/entity/Q21129334

description

2011 nî lūn-bûn

@nan

2011 թուականին հրատարակուած գիտական յօդուած

@hyw

2011 թվականին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

@ast

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

@en

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

@en-gb

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

@nl

type

label

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

@ast

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

@en

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

@en-gb

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

@nl

prefLabel

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

@ast

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

@en

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

@en-gb

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

@nl

P1433

Q21129334-EF3DA648-0E65-48DB-A36E-5AC65D7E3A90

P1476

Q21129334-AA1E38D9-3EE0-457C-BD6F-6B3E83225DA6

P2860

Q21129334-01BD12CA-6328-4C2B-95E7-7A33C58369D2

Q21129334-02524B4E-9918-4372-BB04-6D76AD5DF59B

Q21129334-0343DF0C-A248-4A90-A56B-FFB0CE99F41E

Q21129334-047A6C8E-BEF4-4C5B-AFC5-F6E37CC9B5B7

Q21129334-05FCA56C-AB7D-4D66-A574-2742D37B5FF7

Q21129334-097DF0FD-B467-4689-93C0-4A783D3793A7

Q21129334-0A5ED2B1-7A96-4D7C-9B71-1970F01C4A04

Q21129334-0BEDBA50-F6D7-443A-B115-6C77D9F92B2F

Q21129334-0EBE6295-BA2B-4913-84F3-E60432B63DE3

Q21129334-0F978E95-AEE6-4B26-9078-B6BF36097339

P304

Q21129334-114A2F2C-C55B-4218-B21D-81C4DDF84512

P31

Q21129334-F0542586-7701-4955-B62F-1D8B951AF45F

P3181

Q21129334-E6884952-ADF2-4C2C-BE98-EF6075C81670

P356

Q21129334-FD319E11-1946-472E-A56B-C708958C2890

P407

Q21129334-1183CBAB-854F-47FD-AC4D-38C7398396FB

P478

Q21129334-D02484E5-A76C-4723-9182-D46603863F6E

P50

Q21129334-79DF23D0-E736-4E97-BC9B-7B63B5340C7C

Q21129334-83A17CE8-2280-48E6-814F-816D45571337

P577

Q21129334-52205A89-9832-4EF0-AD14-E20927DABE35

P5875

Q21129334-6802B1EF-F161-49B5-B02E-6EFCB6622B63

P698

Q21129334-F73EDDEC-35F3-4562-AC3F-0F8C0351CC1F

P932

Q21129334-A33943D0-2E6E-40E1-B6FA-B25D1C9A56DD

P3181

P356

FNMOL.2011.00032

P1433

Frontiers in molecular neuroscience

P1476

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

@en

P2860

Indirubins deplete striatal monoamines in the intact and MPTP-treated mouse brain and block kainate-induced striatal astrogliosis

GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis

Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin.

Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling

GSK-3: tricks of the trade for a multi-tasking kinase

A molecular mechanism for the effect of lithium on development

The selectivity of protein kinase inhibitors: a further update

Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics

Lithium facilitates apoptotic signaling induced by activation of the Fas death domain-containing receptor

Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent

P304

32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2422765

http://www.w3.org/2001/XMLSchema#string

P356

10.3389/FNMOL.2011.00032

http://www.w3.org/2001/XMLSchema#string

P407

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Hagit Eldar-Finkelman

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228090845

http://www.w3.org/2001/XMLSchema#string

P698

22065134

http://www.w3.org/2001/XMLSchema#string

P932

3204427

http://www.w3.org/2001/XMLSchema#string